Mr. Rajnish Ohri reports

TILRAY MEDICAL ACCELERATES THE COMMERCIAL EXPANSION OF TILRAY MEDICAL-BRANDED CANNABIS MEDICINES IN THE UK WITH FIRST DIRECT-TO-PATIENT LAUNCH THROUGH LYPHE CLINIC AND LYPHE DISPENSARY

Tilray Medical, a division of Tilray Brands Inc., has launched, in the United Kingdom, Tilray Medical-branded cannabis flower products through Lyphe Clinic and Lyphe Dispensary, creating a direct-to-patient channel that broadens access for patients across the country and supports the continued commercial growth of Tilray Medical-branded cannabis medicines in the U.K.

The launch marks an important milestone in Tilray's integration of Lyphe Group and demonstrates the company's differentiated medical cannabis platform in the U.K., bringing together European cultivation, pharmaceutical manufacturing, clinical care, prescribing, dispensing and patient support within a connected health care model.

Rajnish Ohri, president, international, Tilray Brands, stated: "This launch is a defining step in Tilray Medical's U.K. strategy and a powerful example of how we are building a more connected, patient-centered medical cannabis platform. By bringing Tilray Medical-branded cannabis medicines to patients through Lyphe Clinic and Lyphe Dispensary, we are combining high-quality European cultivation and pharmaceutical manufacturing with trusted clinical, prescribing, dispensing, and patient care services. This integrated model strengthens responsible access for patients, supports health care practitioners and reinforces Tilray Medical's commercial leadership in regulated medical cannabis markets."

Tilray Brands acquired Lyphe Group in April, 2026, establishing a differentiated U.K. medical cannabis platform spanning clinical care, prescribing, dispensing and pharmaceutical distribution. The addition of Tilray Medical products to Lyphe Clinic and Lyphe Dispensary strengthens this model by connecting Tilray Medical's global production network with Lyphe's established patient and pharmacy infrastructure.

The rollout reflects Tilray Medical's commitment to responsible access across regulated international medical cannabis markets, and leverages the scale, quality standards and supply-chain capabilities of its global operations. The range available through Lyphe Clinic and Lyphe Dispensary is expected to expand over the coming months, with Tilray Medical products cultivated and produced through the company's international production network, including its European Union good manufacturing practice-certified facility in Portugal.

About Tilray Medical

Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Good Supply, Redecan, ARX and Broken Coast. Tilray grew from one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers and governments in 20 countries across five continents.

About Tilray Brands Inc.

Tilray Brands is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America. Tilray is building a transformative platform at the nexus of cannabis, beverage, wellness and entertainment, elevating lives through moments of connection. Tilray's mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray's unprecedented platform supports over 40 brands in more than 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages.

We seek Safe Harbor.